JP2023542737A5 - - Google Patents

Info

Publication number
JP2023542737A5
JP2023542737A5 JP2023519633A JP2023519633A JP2023542737A5 JP 2023542737 A5 JP2023542737 A5 JP 2023542737A5 JP 2023519633 A JP2023519633 A JP 2023519633A JP 2023519633 A JP2023519633 A JP 2023519633A JP 2023542737 A5 JP2023542737 A5 JP 2023542737A5
Authority
JP
Japan
Prior art keywords
igg
substitution
amino acid
modified
modified igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023519633A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023542737A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/052579 external-priority patent/WO2022072446A1/en
Publication of JP2023542737A publication Critical patent/JP2023542737A/ja
Publication of JP2023542737A5 publication Critical patent/JP2023542737A5/ja
Pending legal-status Critical Current

Links

JP2023519633A 2020-09-29 2021-09-29 ネコ科動物抗体バリアント Pending JP2023542737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063084693P 2020-09-29 2020-09-29
US63/084,693 2020-09-29
PCT/US2021/052579 WO2022072446A1 (en) 2020-09-29 2021-09-29 Feline antibody variants

Publications (2)

Publication Number Publication Date
JP2023542737A JP2023542737A (ja) 2023-10-11
JP2023542737A5 true JP2023542737A5 (cg-RX-API-DMAC10.html) 2024-10-02

Family

ID=78599139

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519633A Pending JP2023542737A (ja) 2020-09-29 2021-09-29 ネコ科動物抗体バリアント

Country Status (16)

Country Link
US (2) US12612455B2 (cg-RX-API-DMAC10.html)
EP (2) EP4221744A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023542737A (cg-RX-API-DMAC10.html)
KR (1) KR20230091914A (cg-RX-API-DMAC10.html)
CN (1) CN116457369A (cg-RX-API-DMAC10.html)
AR (1) AR123645A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021352395A1 (cg-RX-API-DMAC10.html)
CA (1) CA3195049A1 (cg-RX-API-DMAC10.html)
CL (2) CL2023000914A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023004107A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23030307A (cg-RX-API-DMAC10.html)
IL (1) IL301414A (cg-RX-API-DMAC10.html)
MX (1) MX2023003694A (cg-RX-API-DMAC10.html)
PE (1) PE20240110A1 (cg-RX-API-DMAC10.html)
TW (3) TW202545990A (cg-RX-API-DMAC10.html)
WO (1) WO2022072446A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions
WO2026136223A1 (en) * 2024-12-19 2026-06-25 Zoetis Services Llc Compositions and methods for improving feline antibody functions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
KR101616758B1 (ko) * 2007-12-26 2016-04-29 젠코어 인코포레이티드 FcRn에 대한 변경된 결합성을 갖는 Fc 변이체
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
EP3866842A4 (en) 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
WO2020116560A1 (ja) * 2018-12-05 2020-06-11 株式会社バイカ・セラピュティクス 抗体のFc領域改変体
EP4136109A1 (en) 2020-04-17 2023-02-22 Zoetis Services LLC Feline antibody variants
IL301414A (en) 2020-09-29 2023-05-01 Zoetis Services Llc Feline antibody variants
US20240400708A1 (en) 2020-12-18 2024-12-05 Zoetis Services Llc Mutations in feline antibody constant regions

Similar Documents

Publication Publication Date Title
JP2023522030A5 (cg-RX-API-DMAC10.html)
JP2023522029A5 (cg-RX-API-DMAC10.html)
JP6839101B2 (ja) ヘテロ二量体多重特異性抗体フォーマット
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
KR102247704B1 (ko) 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
TWI585104B (zh) 基於vl和vhh可變區衍生物的高親和力抗聚集抗體
JP2021530236A5 (cg-RX-API-DMAC10.html)
JP2020519643A5 (cg-RX-API-DMAC10.html)
JP2022512043A5 (cg-RX-API-DMAC10.html)
JP7339948B2 (ja) モノクローナル抗体およびその使用法
JP2020515518A5 (cg-RX-API-DMAC10.html)
IL276286B2 (en) FC variants with improved binding to FCRN and extended half-life
KR102706285B1 (ko) 항 인터페론 감마 항체 및 그의 용도
RU2712251C1 (ru) Гуманизированные антитела против участка бета цепи 9-го семейства TRBV9 TKP человека, и способы их применения
JP2020505017A5 (cg-RX-API-DMAC10.html)
JP2022009816A5 (cg-RX-API-DMAC10.html)
JP2020500510A5 (cg-RX-API-DMAC10.html)
SI2573121T1 (en) Antibodies that bind IL-4 and/or IL-13 and their uses
JP2023543262A5 (cg-RX-API-DMAC10.html)
WO2022206900A1 (zh) 抗人血清白蛋白(hsa)的纳米抗体及其应用
JP2018148915A5 (cg-RX-API-DMAC10.html)
US20230212321A1 (en) Methods and means for the production of ig-like molecules
JP2024516098A5 (cg-RX-API-DMAC10.html)
JP2021506310A5 (cg-RX-API-DMAC10.html)
JP2024531346A5 (cg-RX-API-DMAC10.html)